CHARLES RIVER LABORATORIES (CRL) Fundamental Analysis & Valuation
NYSE:CRL • US1598641074
Current stock price
173.89 USD
-1.01 (-0.58%)
At close:
173.89 USD
0 (0%)
After Hours:
This CRL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. CRL Profitability Analysis
1.1 Basic Checks
- In the past year CRL was profitable.
- CRL had a positive operating cash flow in the past year.
- CRL had positive earnings in 4 of the past 5 years.
- In the past 5 years CRL always reported a positive cash flow from operatings.
1.2 Ratios
- CRL has a better Return On Assets (-2.02%) than 60.71% of its industry peers.
- CRL has a better Return On Equity (-4.56%) than 60.71% of its industry peers.
- With a decent Return On Invested Capital value of 6.60%, CRL is doing good in the industry, outperforming 76.79% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for CRL is below the industry average of 11.38%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.02% | ||
| ROE | -4.56% | ||
| ROIC | 6.6% |
ROA(3y)1.3%
ROA(5y)3.17%
ROE(3y)2.98%
ROE(5y)8.14%
ROIC(3y)6.85%
ROIC(5y)7.38%
1.3 Margins
- CRL's Operating Margin of 12.51% is fine compared to the rest of the industry. CRL outperforms 73.21% of its industry peers.
- CRL's Operating Margin has declined in the last couple of years.
- The Gross Margin of CRL (34.98%) is worse than 62.50% of its industry peers.
- In the last couple of years the Gross Margin of CRL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.51% | ||
| PM (TTM) | N/A | ||
| GM | 34.98% |
OM growth 3Y-8.99%
OM growth 5Y-4.24%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.96%
2. CRL Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CRL is destroying value.
- CRL has less shares outstanding than it did 1 year ago.
- CRL has less shares outstanding than it did 5 years ago.
- CRL has a worse debt/assets ratio than last year.
2.2 Solvency
- CRL has an Altman-Z score of 2.42. This is not the best score and indicates that CRL is in the grey zone with still only limited risk for bankruptcy at the moment.
- The Altman-Z score of CRL (2.42) is better than 62.50% of its industry peers.
- The Debt to FCF ratio of CRL is 4.13, which is a neutral value as it means it would take CRL, 4.13 years of fcf income to pay off all of its debts.
- Looking at the Debt to FCF ratio, with a value of 4.13, CRL is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
- CRL has a Debt/Equity ratio of 0.68. This is a neutral value indicating CRL is somewhat dependend on debt financing.
- The Debt to Equity ratio of CRL (0.68) is worse than 69.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.68 | ||
| Debt/FCF | 4.13 | ||
| Altman-Z | 2.42 |
ROIC/WACC0.63
WACC10.52%
2.3 Liquidity
- CRL has a Current Ratio of 1.29. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
- CRL has a worse Current ratio (1.29) than 82.14% of its industry peers.
- A Quick Ratio of 1.02 indicates that CRL should not have too much problems paying its short term obligations.
- With a Quick ratio value of 1.02, CRL is not doing good in the industry: 82.14% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.02 |
3. CRL Growth Analysis
3.1 Past
- The earnings per share for CRL have decreased by -0.39% in the last year.
- CRL shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 4.78% yearly.
- Looking at the last year, CRL shows a decrease in Revenue. The Revenue has decreased by -0.85% in the last year.
- The Revenue has been growing slightly by 6.55% on average over the past years.
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y0.33%
Revenue growth 5Y6.55%
Sales Q2Q%-0.83%
3.2 Future
- The Earnings Per Share is expected to grow by 9.31% on average over the next years. This is quite good.
- Based on estimates for the next years, CRL will show a small growth in Revenue. The Revenue will grow by 3.54% on average per year.
EPS Next Y8.47%
EPS Next 2Y8.74%
EPS Next 3Y8.89%
EPS Next 5Y9.31%
Revenue Next Year-0.59%
Revenue Next 2Y1.18%
Revenue Next 3Y2.21%
Revenue Next 5Y3.54%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. CRL Valuation Analysis
4.1 Price/Earnings Ratio
- CRL is valuated correctly with a Price/Earnings ratio of 16.92.
- Based on the Price/Earnings ratio, CRL is valued cheaply inside the industry as 91.07% of the companies are valued more expensively.
- CRL's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.17.
- A Price/Forward Earnings ratio of 15.59 indicates a correct valuation of CRL.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 89.29% of the companies listed in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 23.05. CRL is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.92 | ||
| Fwd PE | 15.59 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, CRL is valued cheaply inside the industry as 94.64% of the companies are valued more expensively.
- 89.29% of the companies in the same industry are more expensive than CRL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.51 | ||
| EV/EBITDA | 11.58 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)2
PEG (5Y)3.54
EPS Next 2Y8.74%
EPS Next 3Y8.89%
5. CRL Dividend Analysis
5.1 Amount
- No dividends for CRL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CRL Fundamentals: All Metrics, Ratios and Statistics
173.89
-1.01 (-0.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-18 2026-02-18/bmo
Earnings (Next)05-05 2026-05-05/bmo
Inst Owners110.03%
Inst Owner Change-0.02%
Ins Owners0.94%
Ins Owner Change5.84%
Market Cap8.56B
Revenue(TTM)4.02B
Net Income(TTM)-144.34M
Analysts78.26
Price Target206.34 (18.66%)
Short Float %7.72%
Short Ratio3.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.93%
Min EPS beat(2)0.98%
Max EPS beat(2)2.88%
EPS beat(4)4
Avg EPS beat(4)9.75%
Min EPS beat(4)0.98%
Max EPS beat(4)23.68%
EPS beat(8)8
Avg EPS beat(8)9.14%
EPS beat(12)12
Avg EPS beat(12)7.96%
EPS beat(16)16
Avg EPS beat(16)6.74%
Revenue beat(2)1
Avg Revenue beat(2)0.06%
Min Revenue beat(2)-0.27%
Max Revenue beat(2)0.38%
Revenue beat(4)3
Avg Revenue beat(4)1.83%
Min Revenue beat(4)-0.27%
Max Revenue beat(4)3.74%
Revenue beat(8)6
Avg Revenue beat(8)1.34%
Revenue beat(12)9
Avg Revenue beat(12)1.37%
Revenue beat(16)11
Avg Revenue beat(16)1.18%
PT rev (1m)0.03%
PT rev (3m)2.47%
EPS NQ rev (1m)-0.26%
EPS NQ rev (3m)-25.21%
EPS NY rev (1m)0%
EPS NY rev (3m)1.64%
Revenue NQ rev (1m)-0.14%
Revenue NQ rev (3m)-1.82%
Revenue NY rev (1m)-1.88%
Revenue NY rev (3m)-2.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.92 | ||
| Fwd PE | 15.59 | ||
| P/S | 2.13 | ||
| P/FCF | 16.51 | ||
| P/OCF | 11.61 | ||
| P/B | 2.71 | ||
| P/tB | 141.77 | ||
| EV/EBITDA | 11.58 |
EPS(TTM)10.28
EY5.91%
EPS(NY)11.15
Fwd EY6.41%
FCF(TTM)10.53
FCFY6.06%
OCF(TTM)14.98
OCFY8.62%
SpS81.56
BVpS64.28
TBVpS1.23
PEG (NY)2
PEG (5Y)3.54
Graham Number121.94
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.02% | ||
| ROE | -4.56% | ||
| ROCE | 8.35% | ||
| ROIC | 6.6% | ||
| ROICexc | 6.84% | ||
| ROICexgc | 14.71% | ||
| OM | 12.51% | ||
| PM (TTM) | N/A | ||
| GM | 34.98% | ||
| FCFM | 12.91% |
ROA(3y)1.3%
ROA(5y)3.17%
ROE(3y)2.98%
ROE(5y)8.14%
ROIC(3y)6.85%
ROIC(5y)7.38%
ROICexc(3y)7.1%
ROICexc(5y)7.66%
ROICexgc(3y)16.12%
ROICexgc(5y)18.95%
ROCE(3y)8.67%
ROCE(5y)9.34%
ROICexgc growth 3Y-11.32%
ROICexgc growth 5Y-5.63%
ROICexc growth 3Y-6.27%
ROICexc growth 5Y-3.36%
OM growth 3Y-8.99%
OM growth 5Y-4.24%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.96%
F-Score5
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.68 | ||
| Debt/FCF | 4.13 | ||
| Debt/EBITDA | 2.36 | ||
| Cap/Depr | 54.34% | ||
| Cap/Sales | 5.46% | ||
| Interest Coverage | 4.94 | ||
| Cash Conversion | 81.47% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z | 2.42 |
F-Score5
WACC10.52%
ROIC/WACC0.63
Cap/Depr(3y)73.38%
Cap/Depr(5y)82.63%
Cap/Sales(3y)6.31%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
EPS Next Y8.47%
EPS Next 2Y8.74%
EPS Next 3Y8.89%
EPS Next 5Y9.31%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y0.33%
Revenue growth 5Y6.55%
Sales Q2Q%-0.83%
Revenue Next Year-0.59%
Revenue Next 2Y1.18%
Revenue Next 3Y2.21%
Revenue Next 5Y3.54%
EBIT growth 1Y-8.84%
EBIT growth 3Y-8.7%
EBIT growth 5Y2.04%
EBIT Next Year25.47%
EBIT Next 3Y11.29%
EBIT Next 5Y9.93%
FCF growth 1Y3.37%
FCF growth 3Y20.69%
FCF growth 5Y6.41%
OCF growth 1Y0.42%
OCF growth 3Y5.98%
OCF growth 5Y6.18%
CHARLES RIVER LABORATORIES / CRL Fundamental Analysis FAQ
What is the fundamental rating for CRL stock?
ChartMill assigns a fundamental rating of 4 / 10 to CRL.
What is the valuation status of CHARLES RIVER LABORATORIES (CRL) stock?
ChartMill assigns a valuation rating of 6 / 10 to CHARLES RIVER LABORATORIES (CRL). This can be considered as Fairly Valued.
Can you provide the profitability details for CHARLES RIVER LABORATORIES?
CHARLES RIVER LABORATORIES (CRL) has a profitability rating of 4 / 10.
What is the valuation of CHARLES RIVER LABORATORIES based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CHARLES RIVER LABORATORIES (CRL) is 16.92 and the Price/Book (PB) ratio is 2.71.
What is the financial health of CHARLES RIVER LABORATORIES (CRL) stock?
The financial health rating of CHARLES RIVER LABORATORIES (CRL) is 4 / 10.